| Literature DB >> 21947806 |
Catherine Rhodes1, John Harris, John Sulston, Catherine Spanswick.
Abstract
There are several good reasons for the UK Department of Health to recommend the appraisal of bevacizumab for the treatment of eye conditions by the National Institute for Health and Clinical Excellence. These reasons will extend to other drugs when similar situations arise in the future.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21947806 PMCID： PMC3541520 DOI： 10.1136/medethics-2011-100032
Source DB: PubMed Journal: J Med Ethics ISSN： 0306-6800 Impact factor: 2.903